Novo Nordisk Terminates Two Heart Disease Drug Trials, Stock Drops Over 10% Cumulatively
nashnova research
Novo Nordisk terminated two heart-failure trials for ziltivekimab after a data panel ruled success was unlikely — the drug's second major setback this year, leaving its cardiovascular pipeline nearly exhausted and the stock down over 10% since late July.
What trials were stopped?
Novo Nordisk halted two clinical trials testing ziltivekimab — an experimental anti-inflammatory heart drug — in heart-failure patients, each targeting a different outcome measure.
A data monitoring committee concluded the trials were "extremely unlikely to yield results different from the earlier failed study."
This means → the decision was not a safety call. The data had already delivered a verdict — continuing would only burn cash.
Hasn't this drug failed before?
Earlier this year, Novo disclosed that ziltivekimab missed its primary endpoint for reducing heart attacks and strokes.
With these heart-failure trials now scrapped, the drug's core cardiovascular pathways are nearly all blocked.
In plain terms = the drug was meant to cover multiple cardiac indications. The two most important routes are both dead ends now.
Is there any path left?
Novo says it will continue one remaining study — evaluating ziltivekimab in patients who have already suffered a heart attack.
This means → the drug's commercial outlook has narrowed from a multi-indication play to a single-shot bet. That last trial's readout will decide whether any value remains.
How has the market reacted?
Novo's shares fell 0.6% in Copenhagen on the day. Since the first trial failure in late July, the stock has dropped more than 10% cumulatively.
This reflects a sustained downward repricing of ziltivekimab expectations, not a one-off shock.
Is this just a Novo Nordisk problem?
No. Novartis recently disclosed that its own experimental cardiac drug also failed to reduce death, heart attacks, and strokes.
This means → back-to-back failures at two pharma giants are raising deeper doubts about the anti-inflammatory mechanism both drugs rely on.
In plain terms = the question is no longer just "does this drug work?" — it is "is this entire therapeutic approach on the wrong track?"
市场有风险，内容仅供研究参考，不构成投资建议。